Editas medicine stock price.

Research Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. ... The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$10 ...See Editas Medicine's detailed income statement and balance sheet. Find out their revenue, expenses and profit or loss over the last fiscal year.A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Select an options expiration date from the drop-down list at the top of the table, and select "Near-the-Money" or "Show All' to view all options. Note: Option ...

The genome editing company's revenue was $6.3 million. That's rather impressive for a clinical-stage biotech, and well up from the roughly $379,000 Editas posted in the second quarter of 2021. Net ...CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it has entered into a definitive agreement with Shoreline Biosciences (Shoreline) for Shoreline to license Editas Medicine’s proprietary SLEEK (SeLection by …

Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed.May 8, 2023 · Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geulah Livshits from Chardan Capital remains neutral on the stock ...Stock analysis for Editas Medicine Inc (EDIT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Editas Medicine, Inc. (EDIT) Stock Forecast & Price Targets - Stock Analysis NASDAQ: EDIT · IEX Real-Time Price · USD Add to Watchlist 10.75 +0.22 …They need the money for the next leg of the journey, and their stock price is as good as it'll likely get until more data comes out. Take Editas Medicine (EDIT 2.28%) as an example. On June 9, it ...

Jun 15, 2023 · CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, before deducting underwriter discounts and commissions and estimated offering expenses.

11.34%. Get the latest Editas Medicine Inc (EDIT) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

View live Editas Medicine, Inc. chart to track its stock's price action. Find market predictions, EDIT financials and market news.Editas Medicine stock price prediction is an act of determining the future value of Editas Medicine shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Editas Medicine's future price could yield a significant profit.Nov 17, 2023 · Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …Robinhood (HOOD 5.91%), in particular, makes this process a breeze with its stock slices option (useful for weighting) and commission-free trading. Put simply, you …Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …

Overview News Editas Medicine Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.71 Market Cap $866.56 M Shares …Editas Medicine, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: EDIT | Nasdaq ... RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating ... Stock Editas Medicine, Inc. - Nasdaq . Consensus Editas Medicine, Inc. CATEGORIES. Indexes; …Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...With Editas Medicine stock trading at $10.49 per share, the total value of Editas Medicine stock (market capitalization) is $856.76M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.

According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ...Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. ... Shares of Editas Medicine (EDIT 2.28%) ...

Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 13.39% so far this month. During the month of March, Editas Medicine Inc’s stock price has reached a high of $9.18 and a low of $7.48. Over the last year, Editas Medicine Inc has hit prices as high as $21.60 and as low as $7.71. Year to date, Editas ...The sale of Editas stock could be related to the biotech's upcoming announcement of clinical data. ... Price as of November 29, 2023, 4:00 p.m. ET ... Keith Speights owns shares of Editas Medicine ...Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.10.68 BATS BZX Real-Time Price As of 3:23pm ET +0.15 / +1.42% Today’s Change 6.08 Today ||| 52-Week Range 11.93 +20.41% Year-to-Date Quote Profile News Charts Forecasts Financials Shareholders...A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 9, 2023 · Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 17.81% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $9.06 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $13.94 and as low as $6.08. Year to date, Editas ... The stock option provides for the purchase of up to 123,350 shares of Editas Medicine common stock at a price of $8.00 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vests over four years, with 25 percent of the shares vesting on the first anniversary of Ms. …Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …10 Mei 2023 ... The consensus price target held steady at US$12.71 despite the upgrade to revenue forecasts and ongoing losses. Analysts seem to think the ...The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.

This might seem like deja vu. Editas Medicine ( EDIT 11.39%) shares soared on Monday. Then on Tuesday. And on Wednesday. The stock is on fire again today, skyrocketing 22.3% as of 11:09 a.m. EST ...

Stock Price Forecast ... The 14 analysts offering 12-month price forecasts for Editas Medicine Inc have a median target of 12.50, with a high estimate of 27.00 ...

According to About.com, how long medicine takes to absorb into the stomach depends on the type of medication, whether it is taken with food or on an empty stomach, and the ability of the medication to pass into the bloodstream.Our information suggests that Editas Medicine, Inc. insiders own under 1% of the company. It appears that the board holds about US$2.6m worth of stock. This …Current Price. $10.58. Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to purchase up to an ...12 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their EDIT share price targets range from $7.00 to $30.00. On average, they expect the company's share price to reach $13.92 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.Why Editas Medicine's Shares Jumped This Week. (Motley Fool) Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, …Insider Monkey’s database tracked Editas Medicine, Inc. (NASDAQ:EDIT) in 8 billionaire portfolios at the end of March. It is one of the top DNA stocks to monitor.Shares of clinical-stage biotech Editas Medicine ( EDIT 3.66%) rose as much as 14% on Monday, lifted by a trend over the past couple of days favoring gene-editing stocks. Editas stock also ...Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions. With Editas Medicine stock trading at $10.49 per share, the total value of Editas Medicine stock (market capitalization) is $856.76M. Editas Medicine stock was originally listed at a price of $18.20 in Feb 3, 2016.

A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.What's more, shares of CRISPR Therapeutics (CRSP-6.39%) have gained 22.6% over the same period, and fellow gene editor Editas Medicine (EDIT-6.64%) also saw its equity rise in price by a healthy ...Stock Quote. Change Volume 52 Week High 52 Week Low Dec 2, 2023 5:42 PM EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. Upcoming Events EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update, December 2023. ... Editas Medicine, Inc. Phone: 617.401.0113 E-mail: [email protected] >> Main …Instagram:https://instagram. msft forecasttruck stocksspr stock forecastfx platforms Why Editas Medicine's Shares Jumped This Week. (Motley Fool) Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, …According to the issued ratings of 12 analysts in the last year, the consensus rating for Editas Medicine stock is Hold based on the current 1 sell rating, 6 hold ratings and 5 buy ratings for EDIT. The average twelve-month price prediction for Editas Medicine is $13.92 with a high price target of $30.00 and a low price target of $7.00. Learn ... making money with optionstop apps for trading In a report released on August 2, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report).The company’s shares closed last Friday at $9.05. According ... best fidelity mutual funds for 2023 Real-time Price Updates for Editas Medicine (EDIT-Q), along with buy or sell indicators, analysis, charts, historical performance, news and moreEditas Medicine Inc stock price (EDIT) NASDAQ: EDIT. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Editas Medicine Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.